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Abstract 1 
The world’s population is rising, leading to an increased global requirement for dietary protein 2 
to support health and adaptation in various populations. Though a strong evidence base has 3 
accumulated to show the nutritional value of animal derived dietary proteins, mounting 4 
challenges associated with sustainability have led to calls for alternative, non-animal derived 5 
dietary protein sources to be investigated. Mycoprotein is a sustainably produced, protein-rich, 6 
high fibre whole food source derived from fungus fermentation. Initial human investigations 7 
demonstrated that mycoprotein consumption can lower circulating cholesterol concentrations. 8 
Recent data also report improved acute postprandial glycaemic control and a potent satiety 9 
effect following mycoprotein ingestion. It is possible that the amount and type of dietary fibre 10 
present in mycoprotein explains these beneficial effects. Emerging data now suggest that the 11 
amino acid composition and bioavailability of mycoprotein may also position it as a promising 12 
dietary protein source to support skeletal muscle protein metabolism. Mycoprotein, therefore, 13 
may be a viable dietary protein source to promote training adaptations in athletes and/or muscle 14 
mass maintenance to support healthy ageing. Herein, we review the current evidence 15 
underlying the metabolic effects of mycoprotein and highlight the key questions that need to 16 
be addressed.   17 
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Introduction 18 
Developing a nutritionally sustainable future is an urgent contemporary issue. The world’s 19 
population is projected to increase from ~7.3 billion to >9 billion by 2050.1 This is coupled 20 
with global trends concerning rises in urbanization, social mobility and wealth creation, all 21 
factors expected to exacerbate global food demand.1 As a result, current and future generations 22 
are required to view developments in our understanding of human nutrition through the lens of 23 
mounting challenges associated with the sustainability of increased production.  24 
When considering global dietary protein production requirements, demographic demands are 25 
also compounded by accumulating scientific data to support protein consumption at levels 26 
greater than currently accepted RDAs in various populations. For instance, evidence suggests 27 
muscle mass maintenance in older adults,2-5 the promotion/retention of muscular training 28 
adaptations in athletes6,7 and successful weight management8 are all supported by modest 29 
increases in dietary protein intake above the currently accepted RDAs. It is clear, therefore, 30 
that the global requirement for dietary protein production is a pressing societal issue that is 31 
gathering momentum.  32 
Crucially, the majority of data supporting the refinement of dietary protein requirements has 33 
been obtained from studies examining the in vivo metabolic handling and/or adaptive responses 34 
to animal-derived protein ingestion e.g. 9,10,11. The carbon, water and land use footprints of 35 
animal-derived protein production are anywhere from 8-80, 50-150 and 30-220 times, 36 
respectively, greater than many plant-based proteins (variation dependent on protein source 37 
and methods used to quantify).12 Furthermore, vegan, vegetarian and flexitarian diets are 38 
increasing in popularity.13 As such, research that investigates non-animal derived protein 39 
sources is applicable to a progressively larger demographic, and the impact of such evidence 40 
will rise correspondingly. It is therefore vital that the scientific community begin to examine 41 
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the metabolic handling and nutritional value of alternative, non-animal derived sustainable 42 
protein sources.  43 
 44 
Mycoprotein 45 
Mycoprotein is a whole food source produced by continuous flow fermentation of the 46 
filamentous fungus Fusarium venenatum (for a detailed description of the production processes 47 
please see reference 14).  The resultant product is a high protein, high fibre, and relatively low 48 
energy complete food source (see Tables 115-17 and 215,16) that is textured (via freezing) and 49 
flavoured into a variety of products under the trade name Quorn (Marlow Foods, Stokesley, 50 
North Yorkshire, UK). Importantly, the sustainability credentials of mycoprotein production 51 
position it as an attractive alternative protein source to temper environmental concerns 52 
associated with increased dietary protein production18,19 (see Figure 1).  53 
Following its development in the 1960s, initial human experimentation during the 1970s 54 
established the basic feasibility, tolerability and metabolic impact of mycoprotein 55 
consumption, prior to it being available for general sale in 1985. By the end of the 1990s this 56 
human research had begun to wane, with a complete list and summary of published human 57 
mycoprotein studies performed to date shown in Table 315,20-31. However, the now fully 58 
established commercial viability, environmental advantages, and alternative potential 59 
applications of mycoprotein for metabolic health, skeletal muscle maintenance and 60 
reconditioning has recently reignited research interest in this novel food source.   61 
 62 
Mycoprotein, dietary fibre and cardio-metabolic health  63 
An initial human investigation aimed at establishing tolerability of mycoprotein made an 64 
interesting ancillary observation.20 Human volunteers who consumed 20 g mycoprotein (dry 65 
weight) per day for 30 days (consumed as supplemental cookies) showed a ~7% decrease in 66 
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blood cholesterol concentrations (from 4.86 to 4.53 mmol/L),20 which replicated earlier 67 
findings in animals.32-34 Early research was then focussed in the potential health impact of 68 
mycoprotein upon its dietary fibre content. This was due to an established body of 69 
epidemiological studies reliably showing that higher fibre intakes (typically from fruit, 70 
vegetables and cereals) are associated with reduced blood cholesterol concentrations, improved 71 
blood lipid profiles, and reduced incidence of myocardial infarction and coronary heart 72 
disease.35-38 Such findings have been confirmed during intervention studies where increasing 73 
dietary fibre consumption has been reported to improve peripheral insulin sensitivity, and lower 74 
blood cholesterol concentrations and glycated haemoglobin (HBA1c) in both healthy 75 
individuals and patients with type-2 diabetes.39,40  76 
Follow-up studies focussing on mycoprotein consumption and cardio-metabolic health 77 
confirmed and extended on these effects on blood lipid profiles.21,22 Turnbull and colleagues21 78 
performed a 3-week dietary intervention study where 191 g mycoprotein containing products 79 
(around 40 g dry weight of mycoprotein) was consumed per day, as part of a fully controlled 80 
and laboratory supervised diet aimed at maintaining energy balance in individuals with mildly 81 
elevated blood cholesterol concentrations. This tightly controlled study revealed that the 82 
mycoprotein intervention resulted in reduced blood total cholesterol (from 5.54 to 4.81 83 
mmol/L; 13% decrease) and low density lipoprotein (LDL) cholesterol (from 4.16 to 3.78 84 
mmol/L; 9% decrease) concentrations, and an increase in high density lipoprotein (HDL) 85 
cholesterol (from 0.58 to 0.65 mmol/L; 12% increase) concentrations. These results were even 86 
more striking considering the control group generally showed opposite responses (as opposed 87 
to no change). Given that the energy, macronutrient, lipid composition and cholesterol content 88 
of the diets were similar across groups, it was assumed that fibre content was the causative 89 
component.  90 
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The increased dietary fibre content could conceivably have exerted its cholesterol-lowering 91 
effect by altering LDL cholesterol synthesis/degradation, cholesterol clearance in peripheral 92 
tissues, and/or increased binding of fibre to neutral sterols, cholesterol or bile acids in the 93 
intestine, resulting in decreased cholesterol entering the circulating pool. However, worthy of 94 
note is the beneficial effects of higher fibre diets on circulating cholesterol concentrations do 95 
not always extend to improvements in the specific lipid sub-fractions of LDL and HDL.41 It is 96 
thus interesting to ponder whether the type, rather than simply the amount, of dietary fibre 97 
contained within mycoprotein may, at least in part, explain the beneficial effects of 98 
mycoprotein consumption on circulating cholesterol.  99 
Dietary fibres contained within mycoprotein predominantly comprise 2/3 β-glucan and 1/3 100 
chitin, which form a fibrous insoluble matrix that is relatively rare in more traditional food 101 
sources. In keeping with the importance of fibre type, follow up work by Turnbull and 102 
colleagues22 reported similar effects of mycoprotein consumption (a 0.95 mmol/L or 16% and 103 
a 0.34 mmol/L or 21% reduction in total cholesterol and LDL cholesterol concentrations, 104 
respectively) under free-living conditions despite keeping overall energy, macronutrient and 105 
fibre content (around 6 g) the same across groups. Recent in vitro investigations have dug 106 
deeper mechanistically here, and begun to shed light on potential mechanisms by which the 107 
specific fibre profile of mycoprotein may affect gut microbiota to bring about these cholesterol 108 
lowering effects within humans.  109 
Protein and dietary fibres entering the large intestine become available for fermentation by the 110 
gut microbiota.42 Fermentation of dietary fibres lead to the production of short-chain fatty acids 111 
(SCFA), primarily acetate, propionate and butyrate in a molar ratio of approximately 112 
60:20:20.43 Fermentation of protein derived amino acids leads to production of phenols, 113 
amines, ammonia, branched-chain fatty acids and SCFA. Dietary fibre fermentation is 114 
prioritised over protein fermentation by the gut microbiota, and when fibre fermentation is 115 
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active the fate of dietary protein derived amino acids is bacterial cell biomass as opposed to 116 
metabolism. Therefore, moving from fibre to protein fermentation has also been shown to have 117 
profound effects on the composition of the gut microbiota.44 SCFA production, and propionate 118 
in particular, has been shown to reduce hepatic cholesterol synthesis via inhibition of β-119 
hydroxy-β-methylglutaryl coenzyme A (HMG-CoA) reductase (the rate-limiting enzyme 120 
within cholesterol synthesis),45 and suppress adipose tissue lipolysis.46 In human studies using 121 
inulin propionate ester, which delivers propionate directly to the large intestine, propionate has 122 
been demonstrated to reduce LDL cholesterol and improve liver function and insulin 123 
sensitivity.47,48 However, the current evidence around propionate is inconsistent, with another 124 
study suggesting that its consumption leads to insulin resistance and compensatory 125 
hyperinsulinemia.49 Using in vitro colonic models, mycoprotein and its purified dietary fibre 126 
have been shown to be fermentable, producing SCFA.50 Both mycoprotein and purified 127 
mycoprotein dietary fibre exhibit increased propionate and butyrate production at the cost of 128 
acetate, and increasing colonic propionate production inhibits the incorporation of plasma 129 
acetate into cholesterol.51 Consequently, data are now available to suggest that the digestive 130 
and metabolic properties of the unique fibre profile present within mycoprotein clearly 131 
warrants future (in vivo) research. 132 
The beneficial metabolic effects of mycoprotein consumption have also been shown to extend 133 
to acute postprandial glycaemic control.28,31 It was reported that 20 g mycoprotein (dry weight) 134 
consumed during an oral glucose tolerance test resulted in reduced post-prandial glycaemia 135 
and insulinaemia compared with an isonitrogenous, isoenergetic control condition (soy and 136 
skimmed milk) in healthy, young adults.28 In a recent study31 reduced post-prandial 137 
insulinaemia, but not glycaemia, was also shown with mycoprotein consumption (around 40 g 138 
dry weight) compared with an energy and macronutrient matched chicken meal in overweight 139 
adults. Again, the causative mechanism is likely linked to the amount (4 and 7 g, respectively) 140 
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and type of fibre contained in mycoprotein in these two studies, as viscous polysaccharides can 141 
reduce post-prandial glycaemia and insulinaemia,52 and 5 g of β-glucan has previously been 142 
shown to alter glycaemia and insulinaemia when consumed with a high carbohydrate load.53 143 
Though the chitin-glucan matrix is insoluble and not viscous, chitin is likely to undergo alkaline 144 
deacetylation to produce the viscous polysaccharide chitosan at some stage of the 145 
gastrointestinal tract. In turn, this may confer resistance to the flow induced by gastrointestinal 146 
motility, reducing the small intestine contact time and resulting in slower gastric emptying and 147 
consequent nutrient absorption.54 Irrespective of the mechanism, importantly for translation to 148 
health, no data are yet available concerning whether these acute effects on post-prandial 149 
glycaemia extend to robust changes in insulin sensitivity and/or habitual glycaemic control 150 
when mycoprotein is incorporated within the daily diet. 151 
 152 
Mycoprotein and weight management 153 
With the growing obesity epidemic and associated health complications in the Western world,55 154 
nutritional approaches to induce and sustain weight loss are desirable. Though weight loss 155 
under laboratory conditions via caloric restriction is relatively straightforward to achieve,56 156 
under free-living conditions this tends to be more difficult. Further, subsequent weight regain 157 
appears to be the major barrier to longer term weight management.57 Primary reasons for these 158 
difficulties include a lack of satiety while maintaining an energy deficit,58 and a decline in basal 159 
metabolic rate due to loss of muscle mass.59,60 Diets relatively high in protein (often referring 160 
to simply maintaining absolute protein intake while creating an energy deficit by restricting 161 
carbohydrate and/or fats) have been suggested as a potential solution to these issues.8,57 For 162 
instance, when volunteers are subjected to ad libitum weight loss diets (i.e. more representative 163 
of free-living attempts at weight loss), those consuming diets higher in protein generally lose 164 
body mass and maintain this loss more effectively than those on lower protein diets.61,62 This 165 
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seems primarily attributable to the satiating effects of protein ingestion, meaning overall energy 166 
intake is lower,61 since isoenergetically controlled weight loss interventions show equivalent 167 
weight loss irrespective of protein content.61,62 It is also true that higher protein diets increase 168 
overall daily energy expenditure due to enhanced diet-induced thermogenesis and energy 169 
expenditure while sleeping, effects which occur irrespective of the protein type consumed.63,64 170 
Furthermore, during isoenergetically controlled weight loss studies, it has typically been shown 171 
that higher protein diets increase the ratio of fat to lean mass loss that comprises overall body 172 
weight loss.65 Taken together, the impact of dietary protein during weight loss on satiety, daily 173 
energy expenditure and lean mass retention likely explain the effective role dietary protein 174 
plays in long term weight loss and management.8,57,61 175 
We have recently reported that mycoprotein leads to the acute thermogenic response following 176 
ingestion typical of other (animal) protein sources,15 and therefore would presumably 177 
contribute to overall daily energy expenditure during a weight loss regimen as described above. 178 
Additionally, mycoprotein and most mycoprotein containing products have a low energy 179 
density. The consumption of low energy density foods is positively associated with reduced ad 180 
libitum energy intake, and positive weight management outcomes.66 As such, the substitution 181 
of high energy density foods for mycoprotein containing products may be an effective tool to 182 
manipulate the energy density of a meal or diet. As a low energy density high protein food 183 
source, it would also have theoretical value in a diet aimed at maintaining protein intake in an 184 
effort to retain lean tissue while in an energy deficit.  185 
The effects of mycoprotein on satiety are also of particular interest. It has been shown 186 
previously that protein sources differ in their capacity to affect satiety.64 For example, gelatin 187 
protein provided as a single meal,67 or provided as a primary protein source over a 36 h 188 
experimental period,64 was reported to suppress appetite to a greater extent when compared 189 
with isonitrogenous milk protein equivalents, which the authors suggested may be related to 190 
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the central effects of amino acid composition. Differences in sensory characteristics, such as 191 
greater viscosity and creaminess, may also play a role in increasing satiety and reducing energy 192 
intake.68-71 Interestingly, Turnbull and colleagues demonstrated that consumption of a 193 
mycoprotein meal resulted in acute appetite suppression and a subsequent reduction in ad 194 
libitum food consumption for the remainder of the day (by 24%), and the following day (by 195 
17%), when compared with an isoenergetic and isonitrogenous chicken meal.23 Similar 196 
findings were reproduced by Burley and colleagues24 and Williamson et al.29 when consuming 197 
around 30 and 10 g dry weight mycoprotein, respectively, and we also reported equivalent 198 
satiety between mycoprotein and milk protein.15 In the Turnbull study,23 the authors attribute 199 
these effects to the greater dietary fibre content of the mycoprotein condition (since the meals 200 
were equivalent for energy and protein intake, fibre was necessarily higher). Additionally, 201 
given the relatively small difference in fibre content between conditions (10 vs 17 g), they also 202 
suggest either the specific type of fibre may be particularly potent, or an effect of slower gastric 203 
emptying may explain these effects. Interestingly, both aspects could ultimately act by 204 
modulating post-prandial (neuro) endocrine responses. However, a recent report of similar 205 
increased satiety effects of mycoprotein compared with chicken in overweight and obese 206 
individuals do not support a role of postprandial secretion of the gut peptide YY (PYY) or the 207 
hormone glucagon-like peptide 1 (GLP-1) (both commonly purported to play a role in appetite 208 
suppression with food intake) as a causative mechanism.31  209 
It is possible that various metabolites associated with the partial fermentation of the dietary 210 
fibres may explain the potent appetite suppressive effect of mycoprotein.31 For example, the 211 
SCFA propionate has been shown to induce PYY and GLP-1 in humans in acute settings and 212 
may in part explain short-term appetite regulating effects of some dietary fibres.47 Both 213 
mycoprotein and mycoprotein derived dietary fibre promote propionate production, but the 214 
relevance of this mechanism in explaining effects on appetite regulation remains to be fully 215 
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elucidated.50 Irrespective of the mechanism, the effects on satiety, thermogenesis and the high 216 
protein/low energy content of mycoprotein position this food source as an intriguing approach 217 
to support a (ad libitum) diet aimed at weight loss and/or maintenance. Also worthy of note, 218 
lower glycaemic index diets have independently been shown to improve weight maintenance 219 
following weight loss during energy restriction.57 The capacity of mycoprotein to lower the 220 
glycaemic load of a meal or habitual diet adds an additional line of enquiry as to its potential 221 
utility within weight management. Well controlled longer-term laboratory weight loss studies 222 
comparing mycoprotein with other protein sources are warranted.  223 
 224 
Mycoprotein and skeletal muscle adaptation 225 
Adequate dietary protein intake is required for skeletal muscle mass maintenance and 226 
reconditioning. Skeletal muscle mass and its protein quality are maintained (or improved) 227 
through dynamic fluctuations in the rates of muscle protein synthesis and breakdown. In the 228 
overnight, fasted state muscle protein breakdown rates exceed muscle protein synthesis rates, 229 
leading to net muscle protein loss.72 Protein ingestion transiently (2-5 h) increases muscle 230 
protein synthesis rates,73 primarily due to elevated plasma essential amino acids74 of which 231 
leucine is of particular relevance.10,75 Protein ingestion also stimulates pancreatic insulin 232 
secretion which inhibits muscle protein breakdown,76 contributing to net muscle protein 233 
accretion (‘the anabolic response’) in the post-prandial state, and offsetting fasted protein 234 
losses. It is these diurnal oscillations in muscle protein balance which ultimately allow 235 
individuals to maintain muscle mass.  236 
Individuals performing structured and prolonged physical activity will elicit skeletal muscle 237 
adaptive responses, such as increased muscle mass, muscle quality, contractile function, and/or 238 
muscle oxidative capacity. Performing physical activity stimulates muscle protein synthesis 239 
rates, and to a lesser extent muscle protein breakdown rates, improving muscle protein balance 240 
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for up to 48 h.77 The accumulation of periods of exercise-induced muscle protein accretion 241 
ultimately drives skeletal muscle reconditioning. Following resistance training, this response 242 
primarily comprises the synthesis of myofibrillar proteins to support strength and mass related 243 
adaptations.78 Conversely, in response to endurance exercise, it is predominantly mitochondrial 244 
proteins which are synthesised to facilitate improved oxidative capacity.78 Consuming dietary 245 
protein in close temporal proximity to physical activity is an established strategy to further 246 
augment the muscle protein synthetic response compared with either stimulus alone.79,80 As a 247 
result, strategically (and modestly) increasing dietary protein consumption during prolonged 248 
training augments the skeletal muscle adaptive response to exercise training.81,82 249 
Since post-prandial muscle protein breakdown rates appear to be maximally inhibited with only 250 
mild elevations in circulating insulin,83 the anabolic potential of (post-exercise) dietary protein 251 
ingestion is assumed to be contingent on its capacity to stimulate muscle protein synthesis rates. 252 
Animal-derived proteins typically show high bioavailability and consequent rapid and/or 253 
sustained post-prandial aminoacidaemia and/or leucinaemia following ingestion.10,84-86 As a 254 
result, animal-derived dietary protein sources have been shown to be superior to plant-based 255 
protein sources in their capacity to stimulate muscle protein synthesis rates in humans.86,87 256 
However, to date, wheat and soy (both relatively low in leucine and/or essential amino acids88) 257 
are the only non-animal derived protein sources to be evaluated for their anabolic potential. 258 
Mycoprotein is rich in essential amino acids (see Table 2) (~41% of total protein) and relatively 259 
high in leucine (~6% of total protein), and possesses a high PDCAAS score (0.99; an indirect 260 
indication of a protein’s digestibility). Based on this, we recently addressed whether these 261 
properties of mycoprotein translated to a high in vivo amino acid bioavailability compared with 262 
milk protein.15 We selected milk protein as the control comparator since this contains a high 263 
essential amino acid (~49% of total protein) and leucine content (~11% of total protein), a 264 
PDCAAS score of 1.0, and is consequently typically thought of as a near gold standard with 265 
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respect to its potency for stimulating muscle protein synthesis rates89 and optimising training 266 
adaptations.90 We showed, in healthy young men, that the bioavailability of essential amino 267 
acids and leucine in the hours following ingestion of protein matched boluses of milk protein 268 
and mycoprotein were equivalent (though less rapid, and more sustained with mycoprotein 269 
ingestion).15 It is of note that to protein match these conditions approximately double the mass 270 
(and energy) of mycoprotein was consumed due to its ‘whole food’ nature. We went on to show 271 
that the amino acid bioavailability of mycoprotein increases in a dose-response fashion until 272 
between 60 and 80 g of mycoprotein (i.e. 27-36 g of protein; 2.1-2.9 g leucine) is consumed. 273 
As such, it seems likely that mycoprotein ingestion would stimulate a robust and, in larger 274 
quantities, optimal muscle protein synthetic response and thus be an alternative protein source 275 
to support muscle tissue reconditioning during prolonged training – questions which remain to 276 
be addressed. However, the magnitude of this response when compared with other protein 277 
sources would presumably depend on whether the overall systemic availability of (essential) 278 
amino acids or the speed at which they become available is the more crucial regulatory 279 
factor.84,91  280 
An interesting additional consideration is that mycoprotein represents a whole food source, 281 
rather than an isolated protein. The latter has generally been employed in studies addressing 282 
post-prandial muscle protein synthetic responses. While co-ingestion of carbohydrates or fats 283 
with isolated protein do not seem to modulate the postprandial muscle protein synthetic 284 
response,92-94 emerging data indicate that protein consumed within a whole food source may 285 
confer an anabolic advantage.95,96 It is not clear whether such effects are attributable to differing 286 
energy, macro/micronutrient contents, or aspects relating to a protein source’s specific food 287 
matrix. However, the relevance of evaluating the anabolic response to whole food sources is 288 
emerging as a key research area necessary to translate laboratory findings into information to 289 
refine dietary protein recommendations.96-98 290 
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 291 
Mycoprotein and sarcopenia 292 
In concert with a rising overall population, global demographics also indicate the number of 293 
individuals aged ≥60 years is set to triple by the year 2050, with the fastest growing sub-294 
population being those aged over 85 years.99 A key hallmark of ageing is a progressive loss of 295 
skeletal muscle mass, strength, and aerobic capacity (termed sarcopenia).100 The association 296 
between muscle loss (mass and quality) and increased incidence of falls, fractures, metabolic 297 
disease and other health complications indicates that the burden of our ageing society on health-298 
care systems will increase dramatically over the upcoming decades. Importantly, it also 299 
underlines the critical role that skeletal muscle mass and quality play in healthy ageing.  300 
Since basal, fasted muscle protein synthesis and breakdown rates do not appear to differ 301 
between healthy young and older adults,11,101-104 in an effort to explain the physiological 302 
mechanisms responsible for age-related sarcopenia, research has recently focussed on the 303 
anabolic response to food intake. Numerous studies have now demonstrated a blunted muscle 304 
protein synthetic response to protein ingestion in older adults11,102,105 and this “anabolic 305 
resistance” is now believed to be a key factor underlying age-related sarcopenia. It has been 306 
shown that anabolic resistance can be effectively compensated for on a per meal basis by 307 
consuming protein in close temporal proximity to physical activity,106 increasing the amount 308 
of protein consumed,85,107 and/or optimising the protein source.10,84 Based on this mechanistic 309 
understanding of senescent muscle protein metabolism, calls from the scientific community to 310 
increase recommended daily amount (and address optimal types) of protein to support healthy 311 
ageing are gaining momentum.3,4,108 Moreover, these recommendations are in line with 312 
epidemiological studies that reliably demonstrate that older adults who consume protein in 313 
excess (i.e. ~1.2 g per kilogram body mass) of the RDA (i.e. 0.8 g per kilogram body mass) 314 
experience lower rates of muscle mass, strength and functional capacity declines.109,110 315 
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A pressing question is therefore arising; ‘where should this dietary protein to support healthy 316 
ageing come from?’ It will become increasingly important that this question be viewed through 317 
the potentially competing interests of where robust nutritional physiological investigation leads 318 
us, and the many issues that comprise environmental and government policy. The muscle 319 
protein synthetic response of senescent muscle to alternative, non-animal derived protein 320 
sources has scarcely been studied.  321 
Whether mycoprotein, based on similar principles as presented above, may provide an effective 322 
and sustainable dietary protein source to support healthy (and active) ageing remains to be 323 
investigated. While promising, the development of age-related anabolic resistance provides a 324 
challenge when considering the utility of mycoprotein. It would be expected that a relatively 325 
large dose of mycoprotein would be required to maximally stimulate the muscle protein 326 
synthetic response in older adults.107 Given that older adults generally display a reduced 327 
appetite compared with younger adults, paired with the potent satiating effect of mycoprotein, 328 
it would follow that consuming sufficient mycoprotein per meal (or over repeated meals to 329 
obtain daily intakes) may be challenging. Careful consideration to the other macronutrients that 330 
compose a higher (myco)protein meal would therefore be required. Clearly future research is 331 
warranted to establish whether mycoprotein could be used to support optimal muscle protein 332 
synthesis rates while avoiding positive or negative energy balance in older adults and therefore 333 
represent a viable strategy to support heathy ageing. 334 
 335 
Conclusions and future directions 336 
Developing sustainable dietary protein sources is a pressing socio-economic and environmental 337 
concern, and there is an obvious need to develop a robust evidence base to inform the use of 338 
such alternative sources. There is evidence that the incorporation of modest amounts of 339 
mycoprotein into the diet positively influences certain circulating lipid sub-fractions, and acute 340 
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mycoprotein ingestion attenuates postprandial glycaemia and/or insulinemia. These data are 341 
striking as they occur in the face of energy balanced conditions (i.e. are not an artefact of lower 342 
overall energy intake and/or consequent weight loss). These responses may be mediated by the 343 
unique digestive and metabolic properties of the chitin and β-glucan fibres present in 344 
mycoprotein, though a comprehensive and in vivo mechanistic understanding remains to be 345 
established. It is unknown how rapidly circulating cholesterol is affected when mycoprotein is 346 
incorporated into the diet, and a full characterisation of the lipid sub-fraction responses are not 347 
yet available. Furthermore, whether alterations of acute postprandial glycaemic control 348 
translate into improved insulin sensitivity and/or habitual glycaemic control when mycoprotein 349 
is incorporated in the daily diet is also unclear. Mycoprotein is a source of nutrients that can 350 
effectively induce satiety as evidenced by a reduced ad libitum energy intake, suggesting it 351 
may be a useful tool within weight management. This is especially true when considered 352 
alongside its potential as a high-quality protein source and as a modulator of postprandial 353 
glycaemia. As such, research into the ability of mycoprotein to modulate habitual glycaemic 354 
control, caloric intake, and weight management is clearly warranted. Emerging data have 355 
reported that mycoprotein is a bioavailable and insulinotropic protein source, and would 356 
therefore be expected to effectively stimulate muscle protein anabolism. Consequently, 357 
mycoprotein ingestion as a dietary protein source to stimulate muscle protein synthesis rates 358 
and promote muscle adaptation and/or maintenance in various populations (e.g. athletes, older 359 
adults) is a natural area of future research.360 
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Key points  
• Environmental concerns over increased dietary protein production requires the 
development of robust investigation into the nutritional value of alternative, sustainably 
produced dietary protein sources.  
• Mycoprotein is a sustainably produced fungal-derived dietary protein source that has 
been shown to improve blood lipid profiles and acute post-prandial glucose control, and 
provides a potent satiety effect. 
• Mycoprotein has a favourable amino acid composition and bioavailability when 
considering its potential to stimulate muscle protein synthesis rates. 
• Future work should assess the anabolic potential of mycoprotein in various situations 
(e.g. resting, exercise) and populations (e.g. athletes, older adults).  
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Figure Legends 
 
Figure 1 Greenhouse gas emissions (kg CO2e) and water usage (litres) required to produce a 
30 g portion of protein from beef mince, milk, chicken, Quorn mince, Quorn pieces, and 
mycoprotein. Data were taken from Carbon Trust (2014) ‘Quorn, beef and chicken footprints’ 
internal report19, and additional data provided by (and reproduced with permission of) the 
Carbon Trust. 
  
 
 
Table 1 – Nutritional content of mycoprotein, commercially available protein isolates, Quorn vegan pieces, and a selection of commonly consumed protein 
sources. 
 
 Nutrient Composition / 100 g  Leucine Matched* 
  
Protein (g) Fat (g) Carbohydrate (g) Fibre (g) 
Energy 
(kcal) 
Energy (Kj) Leucine (g)  Product (g) Protein (g) 
Mycoprotein (dw) 45 13 10 25 340 1423 3.9 
 
64 29 
Whey protein 80 7 5 <0.1 402 1682 8.6 
 
29 23 
Milk protein 80 1 6 <0.1 350 1464 7.0 
 
36 29 
Quorn pieces 15 3 4 5 113 473 1.2 
 
208 32 
Whole egg raw 13 10 <1 <1 143 598 1.1 
 
230 29 
Beef mince (5%) raw 21 5 0 0 137 573 1.7 
 
150 32 
Chicken meat raw 21 3 0 0 119 498 1.6 
 
156 33 
Cod meat raw 18 1 0 0 82 343 1.4 
 
173 31 
 
Data adapted from internal analyses published in part previously,15 from Gorissen et al. (2018),16 and from the USDA Food Composition 
Database.17 Values are approximated based upon the data available. * Reflects the approximate amount of product and protein that is required to 
be consumed to obtain 2.5g leucine.  
  
 
 
Table 2 – Amino acid content of mycoprotein, and commercially available protein isolates. 
Data adapted from internal analyses published in part previously,15 and from Gorissen et al. (2018).16 
Amino Acid Content g / 100g mycoprotein (dw) g / 100g whey protein g / 100g milk protein g / 100g egg protein 
     
Alanine 2.8 4.2 2.6 2.6 
Arginine 3.3 1.7 2.6 2.6 
Aspartic acid 4.6    
Cystine 0.4 0.8 0.2 0.4 
Glutamic Acid 5.6 15.5 16.7 5.1 
Glycine 2.0 1.5 1.5 1.4 
Histidine 1.6 1.4 1.9 0.9 
Iso-Leucine 2.4 3.8 2.9 1.6 
Leucine 3.9 8.6 7 3.6 
Lysine 3.8 7.1 5.9 2.7 
Methionine 1.0 1.8 2.1 1.4 
Phenylalanine 2.3 2.5 3.5 2.3 
Proline 2.0 4.8 7.3 1.8 
Serine 2.3 4 4 3.3 
Threonine 2.5 5.4 3.5 2 
Trypthophan 0.8    
Tyrosine 1.8 2.4 3.8 1.8 
Valine 2.8 3.5 3.6 2 
EAA 20.9 34.1 30.4 16.5 
NEAA 24.6 34.9 38.7 19.0 
BCAA 9.0 15.9 13.5 7.2 
EAA, total essential amino acids; NEAA, total non-essential amino acids; BCAA, total branched chain amino acids. 
 
 
 
Table 3 – Human studies investigating the metabolic effects of mycoprotein 
Reference 
n Participants Type of study Type of 
intervention 
Intervention 
duration  
Study findings 
Udall et al. 
(1984)20 
100 Healthy adults 
Double-blind cross-
over trial 
Mycoprotein-based 
cookie 
supplementation (20 g 
dry wt/day) vs control 
cookies 
30 days 
6.9 % ↓ plasma cholesterol 
 
No changes in body weight and other blood 
markers (glucose, urea, nitrogen, sodium, 
potassium, calcium, phosphorus, uric acid, 
creatinine, lactic acid dehydrogenase, alkaline 
phosphatase, amylase, SGOT, total protein, 
albumin, triglycerides, complete blood count). 
 
No changes in urine markers (pH, glucose, 
protein, ketones, white and red blood cells) 
Turnbull et al. 
(1990)21 
17 (9 
mycoprotein, 8 
control) 
Healthy adults with 
total cholesterol 
between 5.2–6.2 mmol/l 
Randomised 
controlled parallel 
group trial 
Mycoprotein (~191 g 
Quorn/day) vs meat 
during a fully 
controlled diet 
3 weeks 
13% ↓ plasma cholesterol 
9% ↓ plasma LDL (12% ↑ in control group) 
12% ↑ plasma HDL (11% ↓ in control group) 
↓ 53% triglycerides (in both groups) 
 
No differences in body weight and blood 
pressure 
 
No changes in fasting insulin and glucose 
No changes in Apo A-I and Apo-B 
Turnbull et al. 
(1992)22 
21 (11 
mycoprotein, 
10 control) 
Healthy adults 
with total 
cholesterol > 5.2 mmol/l 
Blinded randomised 
controlled parallel 
group trial 
Mycoprotein-based 
cookie 
supplementation (26.9 
g dry wt/day) vs 
control cookies 
8 weeks 
7.9% ↓ plasma cholesterol 
12.6% ↓ plasma LDL 
No changes in plasma HDL cholesterol and 
triglycerides 
No changes in Apo A-I and Apo-B 
 
No differences in body weight 
Turnbull et al. 
(1993)23 
13 
Healthy females (non-
restrained eaters) 
Randomised 
controlled crossover 
trial 
Energy-matched 
mycoprotein-based 
meal vs chicken-based 
meal 
2 days 
24 % ↓ 24 h energy intake on day of the meal 
16.5 % ↓ 24 h energy intake on the day after 
↓ prospective food consumption and desire to 
eat 3 h after meal 
 
 
Burley et al. 
(1993)24  
18 Healthy adults 
Randomised 
controlled crossover 
trial 
Energy-matched 
mycoprotein-based 
meal vs chicken-based 
meal 
2 days 
18 % ↓ energy intake in subsequent meal 
↓ 24 h energy intake on the day of the meal 
(resulting from no compensation after the 
reduction in the subsequent meal) 
No differences in 24 h energy intake on the 
day after  
No overall differences in eating rate and 
motivation to eat. Significant ↓ in hunger 4 h 
after the meal 
Nakamura et al. 
(1994)25  
15 Healthy males 
Randomised 
parallel group trial 
Mycoprotein-based 
cookies/crisps 
supplementation (18 g 
or 24 g dry wt/day) 
8 weeks 
4.3 % ↓ plasma cholesterol in the 24 g 
mycoprotein group 
Ishikawa (1995)26 37 
Hypercholesteraemic 
patients, with total 
cholesterol > 220 mg/dl 
Double-blind 
randomised 
controlled parallel 
group trial 
Mycoprotein-based 
cookie 
supplementation (12 g 
or 24 g dry wt/day) vs 
control cookies 
4 weeks ↓ plasma cholesterol 
Homma et al. 
(1995)27 
52 Healthy males 
Randomised 
crossover trial 
Mycoprotein-based 
crisps 
supplementation (18 g 
or 24 g dry wt/day)  
4 weeks 
6.7 % ↓ plasma cholesterol in the 24 g 
mycoprotein group 
Turnbull & Ward 
(1995)28 
19 Healthy adults 
Double-blind 
randomised 
controlled crossover 
trial 
Mycoprotein-based 
milkshake (20 g dry 
wt) vs control 
milkshake 
120 min 
↓ glycaemia (13% at 60 min) 
↓ insulinaemia (19% at 30 min and 36% at 60 
min) 
Williamson et al. 
(2006)29  
42 
Overweight pre-
menopausal females 
Randomised 
controlled crossover 
trial 
Mycoprotein-based 
preload meal vs tofu 
or chicken based 
preload meals before 
lunch 
1 day 
12,3% ↓ energy intake at lunch 20 mins after 
mycoprotein preload when compared with 
chicken preload 
No difference in intake at dinner (no 
compensation) 
No differences in subjective ratings of hunger 
and satiety 
Ruxton & 
McMillan (2010)30 
31 (21 
mycoprotein, 
10 control) 
Healthy adults 
Controlled parallel 
group trial 
Mycoprotein-based 
diet (≥ 88 g wet; 21 g 
dry wt/day) vs 
animal-based diet 
6 weeks 
↓ plasma cholesterol in individuals with 
baseline cholesterol ≥ 4.19 mmol/L 
 
No changes in total cholesterol, LDL, HDL, 
triglycerides, glucose, blood pressure, BMI 
 
 
and waist circumference for the sample as a 
whole 
Bottin et al. 
(2016)31 
Part A: 36 
 
 
 
 
 
 
 
 
Part B: 14 
Overweight and obese 
adults 
Single-blinded 
randomised 
controlled crossover 
trial 
Part A: Energy 
matched mycoprotein-
based preload meal 
(44, 88 or 132 g wet 
wt) vs chicken-based 
meal (equivalent 
amount of chicken 
and macronutrient 
matched at each 
protein content) 
 
Part B: Macronutrient 
matched mycoprotein-
based meal (132 g of 
wet wt) vs chicken-
based meal  
180 mins 
10% ↓ energy intake at lunch after high 
mycoprotein preload when compared with 
high chicken preload 
9% ↓ 24 h energy intake following 
mycoprotein ingestion 
8%, 12% and 21% ↓ insulin iAUC after low, 
medium and high mycoprotein preload, 
respectively. 
21 % and16% ↓ in Insulinogenic and 
Disposition Indices, respectively, following 
mycoprotein ingestion 
9% ↑ in Matsuda Index following 
mycoprotein ingestion 
 
No differences in appetite ratings 
No differences in postprandial glucose 
concentrations 
No differences in plasma GLP-1 and PYY 
No differences in gastric emptying 
No differences in resting energy expenditure 
and substrate utilisation 
Dunlop et al. 
(2017)15 
12 Healthy males 
Single-blinded 
randomised 
controlled crossover 
trial 
Mycoprotein-based 
drinks (20, 40, 60 and 
80 g dry wt) vs milk 
protein drink 
240 min 
Equivalent postprandial amino acid 
bioavailability between protein matched 
amounts of mycoprotein and milk protein. 
Slower but more sustained hyperinsulinaemia 
and hyperaminoacidaemia compared with 
milk when protein matched. Dose response 
effects on all parameters until 60-80 g 
mycoprotein consumed. 
 
 
APO – Apolipoprotein; GLP-1 - Glucagon-like peptide-1; HDL – High density lipoprotein; iAUC – Incremental area under the curve; LDL – Low density 
lipoprotein; PYY - Peptide YY / Peptide tyrosine tyrosine; SGOT - Serum glutamic oxaloacetic transaminase 
 
